NanoViricidesNYSE American: NNVC

NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of viruses in animal models as it prepares to begin first Phase II trials. NV-387 has successfully completed Phase I clinical trials in healthy subjects, demonstrating excellent safety and tolerability with no drop-outs or adverse events.

NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu virus H5N1. In recent studies, NV-387 outperformed three approved flu medications—Tamiflu (Oseltamivir), Rapivab (Peramivir), and Xofluza (Baloxavir)—in treating severe lung infections caused by the Influenza A/H3N2 virus in animals.

SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.

NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from damage from Influenza A H3N2 in a lethally infection mouse model. Investors welcomed the news, sending shares of NanoViricides (NYSE-A:NNVC) up 11% to US$1.82 in early trade on Thursday.

NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first nanomedicine to be effective in this way.  NV-387 demonstrated an ideal flat blood concentration profile for extended periods upon oral administration in animal models, the company found, which it said allows for sustained antiviral effects with infrequent dosing.

NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood concentration profile that it believes could enable infrequent dosing. The company said when administered intravenously in a non-human primate animal model, NV-387 demonstrated a “highly desirable blood concentration profile.

NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of viral infections including RSV, COVID, and influenzas. CEO Dr Anil Diwan told investors that, if approved, NV-387 could be “as revolutionary an antiviral agent as penicillin was as an anti-bacterial agent.

NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek out licensing and partnering opportunities for its assets and platform technology. The company said it is pursuing licensing and partnership opportunities for its lead asset NV-387 and its NanoViricides (NYSE-A:NNVC) platform technology.

NanoViricides (NYSE-A:NNVC) has been awarded a ‘Buy' rating and $6.50 price target by analysts at EF Hutton following the release of positive data on the anti-influenza A/H3N2 activity of its therapy NV-387. NanoViricides (NYSE-A:NNVC) shares traded hands at $2.17 on Tuesday afternoon.